课题基金 / 基金详情

Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases

Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
用于测定神经退行性疾病生物标志物的高灵敏度免疫测定
批准号:
10255799
负责人:
Simon Bystryak
金额:
$42.29万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-01 至 2023-05-31

项目摘要

项目成果

Simon Bystryak的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract The long-term objective of this proposal is to further develop a photochemical signal amplification method (PSAM) for increasing the sensitivity of conventional enzyme-linked immunosorbent assays (ELISA) for determination of biomarkers for various neurodegenerative diseases, such as Alzheimer’s Disease (AD). Immunoenzymatic methods such as ELISA are widely used in biology and medicine for drug screening, for detecting viruses (including coronaviruses), bacteria, and biomarkers, particularly cytokines and interleukins for cancer and immunological disorders, and biomarkers for neurodegenerative diseases. They are routinely used in manual, semi-automated, and automated systems where high volumes of tests are performed. However, in many cases the sensitivity of ELISA is inadequate. Some of the key biomarkers for early diagnosis of AD include three cerebrospinal fluid (CSF) biomarkers: amyloid ß-42 (Aß-42), which causes formation of oligomeric plaques, total tau (t-tau), and phosphorylated tau (p-tau) (which increases intracellular neurofibrillary tangles (NFTs). To date, there is no sensitive and cost- effective method for the quantification of these three proteins, hindering the diagnosis and progression monitoring of AD. Existing highly sensitive methods are cumbersome and expensive. Therefore, there is an increased necessity for a common ELISA platform to detect low levels of Aß-42, t-tau, p-tau and other biomarkers for various neurodegenerative diseases that is both inexpensive and simple enough to not require specialized laboratory equipment. In our Phase I project, we propose to further develop a very sensitive and inexpensive immunoassay platform for detection of biomarkers for various neurodegenerative diseases. The proposed technology, ELISA + PSAM, consists of two steps: (1) a conventional horseradish peroxidase (HRP)-mediated assay (ELISA) in which a common chromogenic HRP substrate, is used and (2) a substrate solution containing the product of the enzymatic reaction is irradiated by visible light. Illumination of the sample leads to a DAP- catalyzed drastic increase in DAP concentration (autocatalytic photochemical reaction). The Specific aims of Phase I are: 1. To explore all variables affecting the performance of ELISA + PSAM assays for detection of Aß-42, t-tau and p-tau and optimize the performance of the assays. To develop a universal approach for transitioning from ELISA to ELISA + PSAM assays. 2. To validate the universal approach for optimization of ELISA + PSAM assays by using up to 3 commercially available ELISA kits from different manufacturers for each analyte. This will include determination of sensitivity and reproducibility/precision of the assays.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
  • 批准号:
    10698757
  • 项目类别:
  • 资助金额:
    $97.77万
  • 财政年份:
    2021
  • 负责人:
    Simon Bystryak
  • 依托单位:
Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
  • 批准号:
    10513251
  • 项目类别:
  • 资助金额:
    $3.43万
  • 财政年份:
    2021
  • 负责人:
    Simon Bystryak
  • 依托单位:
A new hemagglutination method for blood grouping
  • 批准号:
    8833912
  • 项目类别:
  • 资助金额:
    $49.52万
  • 财政年份:
    2013
  • 负责人:
    Simon Bystryak
  • 依托单位:
A new hemagglutination method for blood grouping
  • 批准号:
    9127323
  • 项目类别:
  • 资助金额:
    $45.98万
  • 财政年份:
    2013
  • 负责人:
    Simon Bystryak
  • 依托单位:
海外基金